Compare Inovio Pharmaceuticals Inc (INO) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 120.3× Inovio Pharmaceuticals Inc's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| INO | XLP | |
|---|---|---|
Market Cap | $112.19M | $13.50B |
Volume | 3,201,278 | 14,599,953 |
Sector | Health | — |
52-Week High | $2.65 | $90.00 |
52-Week Low | $0.66 | $75.61 |
Typical Hold Time | 43 Days | 72 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO Pharmaceuticals trades at $1.09, down 5.63% today, with a bearish technical outlook despite positive analyst sentiment. The company faces significant fundamental challenges with minimal revenue of $65,340 in 2025 and substantial losses of $84.95 million. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, which could transform the company's prospects if approved.
Investment outlook hinges on FDA approval of INO-3107, with analysts maintaining a $2.75 consensus target representing 152% upside. However, persistent cash burn and negative profitability metrics pose substantial risks. The stock offers high-risk, high-reward potential for investors comfortable with binary regulatory outcomes in biotech.
XLP (Consumer Staples Select Sector SPDR ETF) trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong defensive characteristics amid market volatility, with 100% analyst buy ratings and a forthcoming dividend. Recent news highlights its outperformance versus discretionary sectors and competitive positioning against peers like VDC and IYK.
Outlook remains positive given defensive sector strength and favorable expense ratio, though risks include interest rate sensitivity and consumer spending shifts. The ETF's focus on household staples provides stability, but elevated RSI levels suggest near-term consolidation potential before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
